Cargando…
Adenoviral VEGF-D(ΔN ΔC) gene therapy for myocardial ischemia
Background: Cardiovascular diseases are the leading cause of death globally. In spite of the availability of improved treatments, there is still a large group of chronic ischemia patients who suffer from significant symptoms and disability. Thus, there is a clear need to develop new treatment strate...
Autores principales: | Pajula, Juho, Lähteenvuo, Johanna, Lähteenvuo, Markku, Honkonen, Krista, Halonen, Paavo, Hätinen, Olli-Pekka, Kuivanen, Antti, Heikkilä, Minja, Nurro, Jussi, Hartikainen, Juha, Ylä-Herttuala, Seppo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817830/ https://www.ncbi.nlm.nih.gov/pubmed/36619378 http://dx.doi.org/10.3389/fbioe.2022.999226 |
Ejemplares similares
-
Isolation of fresh endothelial cells from porcine heart for cardiovascular studies: a new fast protocol suitable for genomic, transcriptomic and cell biology studies
por: Hätinen, Olli-Pekka A., et al.
Publicado: (2019) -
Adenoviral VEGF-B186R127S gene transfer induces angiogenesis and improves perfusion in ischemic heart
por: Korpela, Henna, et al.
Publicado: (2021) -
Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-D(ΔNΔC) gene therapy eight-year follow-up of phase I KAT301 study
por: Leikas, Aleksi J., et al.
Publicado: (2021) -
Adenoviral intramyocardial VEGF-D(ΔNΔC) gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up
por: Hartikainen, Juha, et al.
Publicado: (2017) -
Adenoviral Gene Therapy Vectors in Clinical Use—Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety
por: Leikas, Aleksi J., et al.
Publicado: (2023)